Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?

Giandomenico Roviello, Navid Sohbani, Roberto Petrioli, Maria Grazia Rodriquenz

Research output: Contribution to journalReview article

Abstract

The second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab, a monoclonal antibody against VEGFR-2, has demonstrated overall survival superiority against placebo as a second line therapy for patients with AFP > 400 ng/ml in the recent REACH-2 trial. This review will provide the current updated knowledge regarding the HCC cancerogenesis and angiogenic VEGF/VEGFR-2 pathways and the clinical development of ramucirumab in advanced HCC. This study will also critically assess the gaps in a previous negative phase III trial that tested other potentially useful treatments and suggest ways to modernise clinical trials and personalise therapy for advanced HCC.

Original languageEnglish
JournalInvestigational New Drugs
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Hepatocellular Carcinoma
Vascular Endothelial Growth Factor Receptor-2
Placebos
Therapeutics
Critical Pathways
Survival
Vascular Endothelial Growth Factor A
Biomarkers
Monoclonal Antibodies
ramucirumab
Clinical Trials

Keywords

  • Alphafetoprotein
  • HCC
  • Ramucirumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Ramucirumab as a second line therapy for advanced HCC : a significant achievement or a wasted opportunity for personalised therapy? / Roviello, Giandomenico; Sohbani, Navid; Petrioli, Roberto; Rodriquenz, Maria Grazia.

In: Investigational New Drugs, 01.01.2019.

Research output: Contribution to journalReview article

@article{962a1ffc586149f281f2b65312fac2f2,
title = "Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?",
abstract = "The second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab, a monoclonal antibody against VEGFR-2, has demonstrated overall survival superiority against placebo as a second line therapy for patients with AFP > 400 ng/ml in the recent REACH-2 trial. This review will provide the current updated knowledge regarding the HCC cancerogenesis and angiogenic VEGF/VEGFR-2 pathways and the clinical development of ramucirumab in advanced HCC. This study will also critically assess the gaps in a previous negative phase III trial that tested other potentially useful treatments and suggest ways to modernise clinical trials and personalise therapy for advanced HCC.",
keywords = "Alphafetoprotein, HCC, Ramucirumab",
author = "Giandomenico Roviello and Navid Sohbani and Roberto Petrioli and Rodriquenz, {Maria Grazia}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10637-019-00760-0",
language = "English",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Ramucirumab as a second line therapy for advanced HCC

T2 - a significant achievement or a wasted opportunity for personalised therapy?

AU - Roviello, Giandomenico

AU - Sohbani, Navid

AU - Petrioli, Roberto

AU - Rodriquenz, Maria Grazia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab, a monoclonal antibody against VEGFR-2, has demonstrated overall survival superiority against placebo as a second line therapy for patients with AFP > 400 ng/ml in the recent REACH-2 trial. This review will provide the current updated knowledge regarding the HCC cancerogenesis and angiogenic VEGF/VEGFR-2 pathways and the clinical development of ramucirumab in advanced HCC. This study will also critically assess the gaps in a previous negative phase III trial that tested other potentially useful treatments and suggest ways to modernise clinical trials and personalise therapy for advanced HCC.

AB - The second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab, a monoclonal antibody against VEGFR-2, has demonstrated overall survival superiority against placebo as a second line therapy for patients with AFP > 400 ng/ml in the recent REACH-2 trial. This review will provide the current updated knowledge regarding the HCC cancerogenesis and angiogenic VEGF/VEGFR-2 pathways and the clinical development of ramucirumab in advanced HCC. This study will also critically assess the gaps in a previous negative phase III trial that tested other potentially useful treatments and suggest ways to modernise clinical trials and personalise therapy for advanced HCC.

KW - Alphafetoprotein

KW - HCC

KW - Ramucirumab

UR - http://www.scopus.com/inward/record.url?scp=85063039573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063039573&partnerID=8YFLogxK

U2 - 10.1007/s10637-019-00760-0

DO - 10.1007/s10637-019-00760-0

M3 - Review article

AN - SCOPUS:85063039573

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

ER -